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high fat or sugar; it is important to note that the contribution 
of altered food preferences to the RYGB effects on body 
weight is not clear.  © 2014 S. Karger AG, Basel 
 Introduction 
 The obesity epidemic and its related comorbidities con-
stitute a major challenge for both personal health and pub-
lic health systems worldwide. The enormous increase in 
the knowledge about the physiological mechanisms con-
trolling eating and body weight contrasts with the lack of 
available pharmacology-based therapies that lead to safe, 
efficient and long-lasting body weight reductions and an 
ensuing reduction in obesity-related comorbidities. Re-
cent insights into underlying mechanisms of obesity and 
bariatric surgery have led to promising perspectives with 
respect to gut hormone-based strategies against obesity. 
However, the best results for maintained weight reduction 
and improvement of comorbidities are still achieved by 
bariatric surgery  [1–4] . This review aims to summarize key 
findings with respect to underlying physiological mecha-
nisms of the Roux-en-Y gastric bypass (RYGB) procedure 
which by many is still considered the gold standard in bar-
iatric surgery. Reference will also be made to vertical sleeve 
gastrectomy (VSG) and to gastric banding (GB).
 Key Words 
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 Abstract 
 Obesity and its related comorbidities can be detrimental for 
the affected individual and challenge public health systems 
worldwide. Currently, the only available treatment options 
leading to clinically significant and maintained body weight 
loss and reduction in obesity-related morbidity and mortal-
ity are based on surgical interventions. Apart from the ‘gold 
standard’ Roux-en-Y gastric bypass (RYGB), the vertical 
sleeve gastrectomy and gastric banding are two frequently 
performed procedures. This review will discuss animal ex-
periments designed to understand the underlying mecha-
nisms of body weight loss after bariatric surgery. While ca-
loric malabsorption and mechanical restriction are no major 
factors in this respect, alterations in gut hormone levels are 
invariably found after RYGB. However, their causal role in 
RYGB effects on eating and body weight has recently been 
challenged. Other potential factors contributing to the RYGB 
effects include increased bile acid concentrations and an al-
tered composition of gut microbiota. RYGB is further associ-
ated with remarkable changes in the preference for different 
dietary components such as a decrease in the preference for 
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 Research with animal models helped to elucidate some 
of the physiological mechanisms that potentially underlie 
the treatment success of bariatric surgery.  Figure 1 illus-
trates schematically the pre- and postoperative anatomy 
of the gastrointestinal tract after RYGB and VSG opera-
tions in rats. Both operations reduce eating at least tem-
porarily and may increase energy expenditure. Both pro-
cedures further lead to changes in food preferences. The 
majority of data collected with the help of preclinical 
studies seem to be consistent with findings in humans. 
However, increases in energy expenditure after RYGB 
seem to be less consistent in humans when compared to 
most animal models; this may be related to the much larg-
er heterogeneity of study populations in humans com-
pared to laboratory animals.
 Current research often focuses on altered concentra-
tions of gut hormones like glucagon-like peptide-1 (GLP-
1) or peptide YY (PYY) and metabolites that per se are 
known to affect eating and to modulate nutrient metabo-
lism. It needs to be pointed out, however, that association 
and causality must not be confounded because measur-
able changes in circulating parameters after bariatric sur-
gery do not necessarily play a causal role in the observed 
effects of bariatric surgery; hence, it is not yet clear wheth-
er these changes are necessary or sufficient for reduced 
eating or body weight. 
 Effects of RYGB on Body Weight 
 RYGB in rats or mice leads to a rapid and marked de-
crease in body weight compared to sham-operated ani-
mals [e.g.  5–7 ]. RYGB-operated rats typically lose about 
20% of their presurgical body weight which then plateaus 
at a constant level; in some studies, body weight is slowly 
regained over time, but without ever reaching the body 
weight of respective control animals. A decrease in body 
fat mass largely accounts for the decrease in body weight, 
while lean body mass is typically preserved. 
 Theoretically, body weight loss after RYGB in com-
parison to sham-operated controls can be explained by 
reduced calorie intake, increased energy expenditure, re-
duced nutrient availability (e.g. caloric malabsorption), 
altered metabolic efficiency or by a combination of all 
these factors. Considering the available literature, re-
duced eating and increased energy expenditure may play 
a much greater role after RYGB surgery than caloric mal-
absorption which seems to be only of minor importance 
for the observed effects of RYGB  [5, 8] . Thus, even 
though the gastrointestinal anatomy is significantly re-
arranged after RYGB and even though the stomach, du-
odenum and proximal jejunum are excluded from the 
flow of ingested food, it seems that the total digestive and 
absorptive capacity of the small bowel still suffices to 
avoid maldigestion and subsequent caloric malabsorp-
Common channel
Alimentary limb
Gastric pouch
Biliopancreatic
limb
 Fig. 1. Schematic representation of the sham operation (left), the RYGB (middle) and the VSG (right) in rats. In 
our laboratory, the different segments of the small intestine after the RYGB operation in rats have the following 
approximate dimensions: biliopancreatic limb 10 cm (green/light grey); alimentary limb (Roux limb) 50 cm (red/
middle grey); common channel 25 cm (blue/dark grey). The gastric pouch has a volume of <5% of the intact 
stomach. 
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tion. This may at least partly be due to the massive hy-
pertrophy of the small bowel that is observed predomi-
nantly in those gut segments that are still in contact with 
nutrients (i.e. alimentary limb and common channel; see 
 fig. 1 )  [5, 9, 10] . It must be noted, however, that the con-
tribution of malabsorption to the RYGB-induced body 
weight loss may increase if animals are maintained on a 
high-fat diet  [11] . Similarly, in our own laboratory, tem-
porary malabsorption may occasionally be observed un-
der conditions of high fat feeding (e.g. 60% fat by calo-
ries), but the contribution to body weight loss seemed to 
be minor.
 Figure 2 indicates that reduced eating is one, but clear-
ly not the only factor contributing to body weight reduc-
tion after RYGB in rats. RYGB rats spontaneously eat less 
after surgery when compared to sham-operated controls; 
however, sham-operated rats that are pair fed to RYGB 
rats have a greater body weight than ad libitum-fed RYGB 
rats. Only if sham-operated rats undergo more severe 
food restriction and get less food offered than RYGB rats, 
do they show a body weight trajectory that is comparable 
to RYGB rats. As caloric malabsorption has been shown 
to only play a minor role  [5] , RYGB rats may have in-
creased energy expenditure, at least compared to body 
weight-matched controls (see below).
 Effect of RYGB on Food Intake and Meal Pattern 
 One important factor that contributes to body weight 
loss after RYGB is a reduction in overall food intake; the 
reduction in eating seems to be a voluntary process since 
studies in humans have shown that pre-meal hunger is 
not higher and post-meal satiation is not lower after 
RYGB despite an overall lower food intake  [12, 13] . In 
most published studies, RYGB leads to a significant re-
duction in eating compared to ad libitum-fed sham-op-
erated rats. RYGB rats typically eat less during the dark 
phase of the light/dark cycle and during an entire 24-hour 
period; interestingly, light-phase food intake is increased 
in at least some studies (see also  fig. 3 )  [5] .
 The reduction in overall food intake is accompanied 
by a typical change in meal pattern  [5, 6, 14] . Interest-
ingly, meal pattern changes in rodent models of RYGB 
resemble those seen in RYGB patients. Both, patients and 
rats seem to eat and drink less and on average ingest 
smaller meals that are consumed with slower eating rates 
after RYGB surgery. Simultaneously, the meal frequency 
increases after RYGB, which however does not compen-
sate for the reduced meal size. Similarities in meal pat-
terns between humans and rats after RYGB suggest that 
the physiological effects of RYGB may rather rely on al-
tered feedback signals from the gastrointestinal tract to 
control centers of eating in the brain than on (confound-
ing) psychosocial influences, including dietary counsel-
ing.
 Interestingly, RYGB rats consume smaller meals in the 
dark phase, but larger meals in the light phase when com-
pared to sham-operated control rats. As a result, RYGB 
rats have approximately the same meal size during the 
dark and light phase while sham-operated rats consume 
significantly more food per meal during the dark phase 
than during the light phase. Furthermore, RYGB rats 
consume significantly more meals during 24 h than
sham-operated rats ( fig. 3 ).
 At first sight, one could argue that an overall increase 
in meal frequency together with a constant meal size in-
dicate the inability of RYGB rats to overcome a mechani-
cal constraint executed by a small gastric pouch; in other 
words, these compensatory mechanisms may be neces-
sary to overcome mechanical restriction in order to 
achieve an acceptable level of total caloric intake. Several 
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 Fig. 2. Development of body weight from the day of operation (day 
0) in sham-operated rats (squares) and RYGB rats (blue/grey cir-
cles). On day 7 after surgery, sham-operated rats were randomized 
to be fed ad libitum (white squares; average daily food intake ap-
prox. 35 g), pair fed to the RYGB rats (red/dark grey squares; aver-
age daily food intake approx. 25 g) or food restricted to match the 
rats’ body weight to that of RYGB rats (green/light grey squares; 
average daily food intake approx. 8 g). Of note, from about 3 weeks 
after surgery, body weight-matched rats received on average about 
50% of the amount of food eaten by the ad libitum-fed rats to main-
tain the same body weight as RYGB rats. Data are shown as mean 
± SEM with n = 6–8 per group. 
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important findings argue against this interpretation. 
Firstly, both humans and rats do not increase their water 
intake with the meal, suggesting that there is no attempt 
to overcome mechanical constraint through food dilu-
tion with water. Secondly, there is no correlation between 
the size of the gastrojejunal anastomosis and weight loss 
in RYGB rats  [15] . Thirdly, blocking the pleiotropic gut 
hormone response in humans after RYGB with a so-
matostatin analogue (which does not change the size of 
the gastric pouch or stoma) can almost double ad libitum 
food intake  [12] ; similar effects are seen in rats  [16] . Fur-
ther, if mechanical restriction were a major factor, one 
would assume that RYGB animals are more hungry than 
sham-operated animals and try to ingest calorically dense 
food to overcome the volume restriction; however, the 
exact opposite is the case because RYGB reduces high-fat 
diet intake relative to low fat intake [e.g.  6, 17 ]. Finally, if 
mechanical constraint were an important factor, then it 
should be impossible to exceed the maximal limit. Thus, 
we food restricted a group of RYGB rats such that they 
received less than half of their ad libitum food intake over 
about 2 weeks with subsequent unlimited access to solid, 
normal chow; RYGB rats increased their food intake as 
soon as ad libitum food was available. Instead of return-
ing to the level of food intake seen in the ad libitum-fed 
RYGB rats, the food-restricted RYGB rats ate significant-
ly more and food intake even exceeded that of sham-op-
erated ad libitum-fed rats ( fig. 4 ). Similarly, Stefater et al. 
[18] have shown that temporary restriction of food access 
lowers body weight in VSG and control animals; when 
returning to an ad libitum feeding regimen, all animals, 
including the VSG rats, overate to compensate for the re-
striction period and reached their pre-restriction body 
weight in a similar time frame. Overall, these data indi-
cate that it appears unlikely that mechanical constraint is 
a major factor of reduced eating and the altered meal pat-
tern after RYGB, but also VSG, because there does not 
seem to be a ceiling effect at the typical level of ad libitum 
food intake after RYGB or VSG.
 RYGB Changes the Gut Morphology in Specific Gut 
Segments 
 The RYGB procedure is associated with typical chang-
es in the morphology of intestinal mucosa [e.g.  5, 9, 10, 
19 ]. This has most consistently been described in RYGB 
rats, and the phenomenon seems to be less marked in 
RYGB mice. In rats, the total length of the small intestine 
remains unaltered, but a marked increase in wet weight 
of the small intestine indicates segmental hypertrophy af-
ter RYGB. Specifically, muscular and mucosal layers are 
significantly thicker in the alimentary (Roux) limb after 
RYGB in comparison with corresponding intestinal seg-
ments in sham-operated controls; both mucosal crypt 
depth and villi height increased. Depending on the di-
mensions of the various limbs after RYGB  [5, 9, 10] , sim-
ilar changes may also be observed in the common channel 
of some RYGB models, but not in the biliopancreatic 
limb.
 The underlying mechanisms leading to hypertrophy of 
the intestinal mucosa including muscle layers remain un-
known. Mechanical or chemical factors or a combination 
of both may be involved. It is however intriguing that not 
all intestinal segments show a hypertrophic response. 
One possible explanation is linked to an increased release 
of GLP-2 from intestinal L-cells  [19] (see also below) fa-
cilitating intestinal hypertrophy in conjunction with in-
traluminal factors such as stimulation by nutrients. Over-
all, it may be postulated that hypertrophy of certain intes-
tinal segments in RYGB animals represents an adaptive 
response to optimize nutrient digestion and absorption 
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 Fig. 3. Meal pattern in rats that were sham 
operated (white bars) or RYGB operated 
(black bars). RYGB rats eat smaller but 
more frequent meals during the dark phase 
or during an entire 24-hour period, respec-
tively; during the light phase, meal size 
slightly increases but meal number does 
not change. Meal pattern analysis was per-
formed 6–8 weeks postoperatively. Data 
are shown as mean ± SEM with n = 6–8 per 
group.  * p < 0.05,  * * p < 0.01,  * * * p < 0.001, 
significant difference between sham-oper-
ated and RYGB rats. 
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under conditions where nutrients and digestive juices 
from the pancreas and liver mix more distally than under 
physiological conditions. Similar responses can be seen in 
experiments where segments of the small intestine have 
been surgically removed.
 Because of the potential importance of gut hormones 
for the beneficial effects of RYGB and other types of bar-
iatric surgery, several groups also investigated whether 
RYGB modifies the distribution or density of enteroen-
docrine cells in the gastrointestinal tract. Consistent with 
the general hypertrophy of the intestinal mucosa, there 
are clear indications for an adaptive increase in the num-
ber of endocrine cells. This translates into an increase in 
the absolute number of L-cells releasing GLP-1, GLP-2 
and PYY, and of cholecystokinin (CCK) immunoreactive 
cells; while major effects were seen in the alimentary limb 
and the common channel, no changes were observed in 
the biliopancreatic limb. Interestingly, however, regional 
density of enteroendocrine cells remains unaltered  [9, 
20] .
 When testing the specific expression of preprogluca-
gon (for GLP-1) and PYY in the intestinal segments, the 
mRNA expression per cell is only increased in the com-
mon channel, but not in the alimentary limb  [20] ; hence, 
it seems that both the (general) stimulus that leads to in-
testinal hypertrophy (perhaps induced by increased GLP-
2 secretions) and the presence of nutrients plus bile acids, 
gastric and pancreatic juices may be necessary to increase 
gastrointestinal hormone production at the level of indi-
vidual cells. Overall, data clearly indicate that the hor-
monal secretory capacity of the small intestine increases 
after RYGB. Further, L-cell density seems to increase 
along the rostrocaudal axis. Importantly, however, it 
must be noted that the majority of the total number of L-
cells is found in more proximal gut segments, and not in 
the ileum, after RYGB surgery in rats  [20] .
 RYGB Surgery Changes the Concentration of 
Circulating Gut Hormones 
 One of the most consistent findings and one of the 
most frequently proposed mechanisms contributing to 
reduced eating and body weight after RYGB surgery is the 
increased secretion of gut hormones, in particular the L-
cell products GLP-1 and PYY, but also amylin and CCK 
 [12, 13, 19, 21, 22] . The single or combined action of these 
satiating hormones provides a plausible explanation for 
the decrease in meal size observed in RYGB rats. The 
blood concentration of ghrelin, in contrast, seems to de-
crease after RYGB, which theoretically could be associ-
ated with a reduced drive to eat; however, data about 
changes in circulating ghrelin are rather inconsistent  [13, 
21, 23, 24] and the relevance of changes in ghrelin secre-
tion, if they occur, is also unclear. Further, it is unclear 
whether the observed changes in ghrelin concentrations 
observed in some studies are physiologically relevant 
modulators of eating; finally, ghrelin-deficient mice 
showed an unaltered body weight-lowering response to 
the VSG procedure  [25] .
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 Fig. 4.  a Body weight in rats that were sham operated (white 
squares) or RYGB operated (grey and black squares) on day 0. Be-
tween postoperative days 15 and 30, part of the RYGB rats (grey 
squares) were food restricted to 50% of the food eaten by the ad 
libitum-fed RYGB rats (black squares).  b Average daily food intake 
from day 15 to 30 (sham: white bar; RYGB ad libitum: black bar; 
RYGB restricted: grey bar). From day 30, all rats had again ad libi-
tum access to food.  c Average daily food intake between days 30 
and 50. Data are shown as mean ± SEM with n = 6–8 per group.
* p < 0.05, *** p < 0.001. 
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 The idea that blood-borne factors play an important 
role in post-RYGB physiology is based on seminal exper-
iments by Atkinson and colleagues who showed that the 
injection of plasma collected postprandially from rats 
with an intestinal bypass reduces eating in recipient rats 
compared to rats receiving postprandial plasma from
sham-operated controls. This effect was not seen if plas-
ma from fasted bypass or sham-operated animals, respec-
tively, was injected into recipient rats  [26] . A large num-
ber of subsequent studies provided evidence for a poten-
tial role of increased secretion of satiating gut hormones 
for RYGB surgery effects [e.g.  13, 19, 21, 27 ]. Most of the 
available data provide correlational evidence, while data 
indicating causality are still scarce. The general belief is 
that RYGB surgery changes nutrient fluxes in such a way 
that an increased secretory stimulus to enteroendocrine 
cells results in increased blood levels of gastrointestinal 
satiation hormones, including GLP-1, PYY, amylin and 
CCK. The effect refers in particular to postprandial con-
centrations of these hormones, but at least in some stud-
ies, the basal concentrations of these hormones are also 
increased; the (physiological) relevance of increased bas-
al levels for the control of eating, however, is not clear.
 Consistent with the idea of an important role of in-
creased gut hormone secretion after RYGB are experiments 
in humans and rats showing that blockade of gut hormone 
release with somatostatin analogues increases eating in 
RYGB patients or rats, respectively  [12, 16] . Further, RYGB 
patients clustered into a group of ‘good responders’ (with a 
body weight loss over approx. 2 years of about 40%) had a 
significantly better postprandial GLP-1 and PYY response 
than patients being classified as ‘poor responders’ (with less 
than 20% body weight loss)  [12] .
 At present, the stimuli leading to increased secretions 
of gut hormones are unknown, and various hypotheses 
have been raised. As discussed above, the general capacity 
to release gut hormones seems to increase markedly as a 
result of the hypertrophy of the small intestinal mucosa  [5, 
9, 10, 19] . However, elevated gut hormones can already be 
observed within few days after surgery, i.e. at a time when 
this hypertrophic response presumably is still negligible. 
One possibility discussed frequently is the higher concen-
tration of nutrients in distal segments of the small intes-
tine. Considering the findings discussed above that the to-
tal number of L-cells is actually much higher in more 
proximal small intestinal segments (hence in the alimen-
tary limb of RYGB animals), undiluted nutrients in the 
alimentary limb may also well be responsible for higher 
secretions of GLP-1, PYY and perhaps CCK. Additionally, 
undiluted bile acid secretions reaching the common limb 
via the biliopancreatic limb of RYGB animals may play an 
important role because it is well documented that luminal 
bile acids directly stimulate L-cell secretion  [28, 29] . At 
present, it is however unclear if the increased expression 
of preproglucagon and PYY and secretion of GLP-1 and 
PYY are directly linked to an increased delivery of bile ac-
ids to L-cells in the common channel; this has not yet been 
studied or compared between RYGB and sham-operated 
rats. Unfortunately, specific antagonists of the bile acid 
receptor (TGR5, also called GPBAR1 [G protein-coupled 
bile acid receptor 1]) that mediates increased L-cell secre-
tions  [28, 29] are not available, and to our knowledge, re-
spective experiments with RYGB-operated TGR5 knock-
out mice have not been performed yet.
 Another open question is how increased basal and post-
prandial amylin secretion is triggered in RYGB rats  [21] . 
It seems unlikely that a direct effect of glucose (or other 
metabolites of carbohydrate metabolism) at the pancreatic 
β-cell plays a role because glucose concentrations are ei-
ther unchanged or rather decrease (in diabetic individuals) 
after RYGB. Increased amylin levels may be caused by a 
stimulating effect of GLP-1 on β-cell secretion, but this has 
so far not been tested after RYGB. Given the therapeutic 
potential of amylin as an anti-obesity treatment  [30, 31] , it 
will be interesting to study the causal contribution of amy-
lin to reduced eating  [32] , body weight  [33, 34] and in-
creased energy expenditure  [35, 36] after RYGB. 
 Increased secretions of GLP-1 and PYY are also typical 
observations after VSG [e.g.  8, 37, 38 ]; similar to RYGB, 
this fueled the idea that the eating inhibitory effect of VSG 
may at least in part depend on the elevated postprandial 
gut hormone levels  [37] .
 Causal Role of Elevated GLP-1 and PYY Levels in the 
Treatment Success of RYGB Surgery 
 The association between elevated concentrations of 
gut hormones like GLP-1, PYY, CCK and amylin on one 
side and reduced eating after RYGB on the other side is 
compelling. However, the evidence for a causal role of 
these gut hormones in reduced eating is surprisingly lim-
ited. Le Roux et al.  [13] have shown that acute pretreat-
ment with a PYY-specific antiserum can reverse the effect 
of bypass on eating in rats, and Chandarana et al.  [39] 
have shown that PYY knockout mice do not lose body 
weight after bypass surgery. It needs to be mentioned that 
the surgical procedures in both studies did not corre-
spond to the true RYGB procedure as it is currently per-
formed in human patients.
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 Our own data with acute blockade of the GLP-1 receptor 
are inconsistent. Acute administration of the GLP-1 recep-
tor antagonist exendin-9 increased eating only in RYGB, 
but not in sham-operated male rats  [40] ; this potentially 
indicates that GLP-1 receptor blockade reverses the effect 
of (exaggerated) GLP-1 levels in RYGB rats. On the other 
hand, exendin-9 increased intake of a test meal in female 
rats after both sham- and RYGB operation to a similar ex-
tent questioning a role of higher GLP-1 levels in RYGB rats, 
at least as a single factor  [41] ; findings were similar when 
using a CCK receptor antagonist. Further, recently pub-
lished data in two different models of whole-body GLP-1 
receptor knockout mice indicated that the GLP-1 receptor 
does not seem to be necessary for most effects induced by 
VSG because knockout and wild-type animals showed very 
similar responses to the VSG procedure  [42] .
 Overall, it must be stated that the causal contribution 
of elevated gut hormone secretions to the beneficial ef-
fects of bariatric surgery procedures may be less clear 
than originally postulated. This is at least true in cases 
where the contribution of single hormones has been test-
ed. Obviously, the RYGB procedure (but also the VSG 
procedure) leads to an entire cocktail of changes in the 
concentrations of many different factors, so that the ma-
nipulation of single aspects (like the use of single knock-
out models) may be unable to mimic the true situation 
after bariatric surgery.
 There is an apparent discrepancy between studies sug-
gesting that blockade of the GLP-1 receptor by specific 
antagonists prevents improvement in glucose homeosta-
sis after VSG  [37, 38] and studies that question an impor-
tant role of the GLP-1 receptor by using GLP-1 receptor 
knockout mice  [42] . Such conflicting results should put 
an additional note of caution on precautious conclusions. 
Each experimental procedure and model bears its advan-
tages and disadvantages, and data must be interpreted 
with care and objectivity; especially because the literature 
does provide multiple pieces of evidence suggesting that 
gut hormones like GLP-1 are indeed important factors for 
the improvement of glucose metabolism after RYGB, 
VSG and other types of bariatric or metabolic surgery 
[e.g.  2, 7, 37, 38, 43 ].
 Extension of RYGB’s Effect on Eating by 
Administration of Exogenous Gut Hormones 
 Even though the average reduction in body weight af-
ter RYGB is impressive, not all patients lose similar 
amounts of excessive weight, and some may even regain 
most of their body weight that was lost initially. Hence, 
supportive therapy options may be needed, particularly 
in patients whose body weight loss is less than expected 
or metabolically needed. The currently available support-
ive therapy options are rather limited, and although revi-
sional surgery in principle is possible (e.g. to further re-
duce the size of the gastric pouch or to shorten the length 
of the common channel), re-dos can be technically very 
demanding and are associated with a higher complication 
rate compared to primary operations. Thus, nonsurgical 
options need to be explored that may help to reach the 
expected goals.
 Recent studies investigated the effect of exogenously 
administered PYY and the GLP-1 agonist exendin-4 on 
eating in RYGB rats  [16, 40] . RYGB led to the expected 
decrease in eating, but it was important to see that RYGB 
rats were still fully responsive to PYY and exendin-4 ad-
ministration; both peptides reduced eating significantly 
in RYGB and sham-operated rats; the degree of food in-
take reduction was comparable or even higher  [40] . In 
other words, despite the increase in basal and postpran-
dial GLP-1 and PYY levels, RYGB rats retain sensitivity 
to the action of these hormones or their agonists, respec-
tively; hence, there is no indication of a desensitization of 
the respective receptor systems. Based on these short-
term experiments, it will be interesting to test whether 
chronic administration of PYY, GLP-1 or their analogues 
also lead to a sustained reduction of eating and decrease 
in body weight under conditions when the effect of bar-
iatric surgery per se is relatively minor; similar studies 
should include amylin  [31] .
 RYGB Surgery Changes the Concentration of 
Circulating Bile Acids 
 As mentioned before, elevated levels of circulating bile 
acids are also a very typical finding after RYGB, and some 
other surgical procedures like ileal interposition [e.g.  44–
47 ]. It has been therefore hypothesized that increased bile 
acid levels may be linked to the metabolic improvement 
after RYGB as bile acids have been suggested to directly 
affect carbohydrate and lipid metabolism, as well as po-
tentially energy expenditure via the (intracellular) bile 
acid receptor FXR. In our own studies, we observed a 
clear increase in fasting levels of circulating bile as soon 
as 8 days after RYGB in rats ( fig. 5 ), but also at later time 
points in diabetic ZDF rats. Data indicating that the in-
tracellular bile acid receptor FXR may be necessary for 
bariatric surgery-induced effects on body weight, glucose 
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and lipid metabolism have been presented at various sci-
entific meetings, but to our knowledge, no such data have 
been published yet.
 RYGB and Gut Microbiota 
 Gut microbiota have been identified as important 
modulators of whole-body energy metabolism  [48, 49] 
and they have been claimed to play a causal role in the 
development (or maintenance) of obesity under different 
feeding conditions  [48] . Interestingly, several studies 
show that the composition of gut microbiota is altered by 
RYGB  [45, 50, 51] and that this effect may be causally 
linked to a reduction in the low-grade inflammatory state 
that follows the reduction in body weight  [51] . Changes 
in gut microbiota seem to be comparable in rodents and 
humans and may in fact not be related to the RYGB-in-
duced changes in eating or body weight, but to the surgi-
cal procedure per se  [50] . Further, changes in gut micro-
biota composition may play a causal role in the body 
weight effects of RYGB surgery because transfer of gut 
microbiota from RYGB mice to germ-free mice reduced 
their body weight compared to mice that received gut mi-
crobiota from sham-operated mice  [50] .
 Because gut microbiota heavily influence bile acid me-
tabolism  [52] , it will be important to test whether altera-
tions in gut microbiota are causally involved in altered 
bile acid metabolism after RYGB, and whether the latter 
is necessary for beneficial effects of RYGB (or other bar-
iatric surgery procedures, respectively)  [2, 3, 43] on insu-
lin sensitivity and whole-body energy metabolism.
 Changes in Energy Expenditure after RYGB Surgery 
 In animal models of RYGB, spontaneous food intake 
is typically reduced in comparison to ad libitum-fed
sham-operated controls. However, lower food intake in 
RYGB rats can only explain part of the body weight loss; 
sham-operated rats that are weight matched to RYGB re-
quire up to 40% less food than RYGB rats to maintain a 
similar level of body weight ( fig.  2 ). As other potential 
explanations such as caloric malabsorption (at least when 
animals are fed standard chow diets; but see  [11] ) or an 
increased inflammatory state after the surgery have been 
shown to be either negligible or absent, energy expendi-
ture after RYGB seems to be higher than in respective 
control animals of similar body weight  [5, 7, 8, 53, 54] .
 In fact, we and a number of other laboratories report-
ed that body weight loss in rats after RYGB is not associ-
ated with the decrease in energy expenditure that can be 
usually observed with traditional weight loss strategies 
such as food restriction or dieting, respectively  [5–7] . 
When energy expenditure determined by indirect calo-
rimetry is corrected for body weight, energy expenditure 
is higher in RYGB rats than in sham-operated ad libitum-
fed and weight-matched controls. However, when calcu-
lating total energy expenditure (i.e. uncorrected for body 
weight), energy expenditure is not consistently increased 
after RYGB; importantly, the comparison to the weight-
matched controls is always positive after both calcula-
tions. Thus, RYGB prevents the (expected) decrease in 
energy expenditure subsequent to body weight loss. This 
fact may well contribute to the long-term maintenance of 
reduced body weight after RYGB operations in humans. 
In some but not all studies, the change in energy expen-
diture is paralleled by a lower respiratory quotient indi-
cating that fat oxidation is increased over carbohydrate 
oxidation. However, the latter may be rather related to 
body weight loss than representing a specific surgical ef-
fect as body weight-matched sham-operated controls 
show a similar response.
 In contrast to preclinical studies in rats, the human lit-
erature is not entirely consistent with respect to RYGB-
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 Fig. 5. Increased fasting concentrations of circulating total bile ac-
ids 8 days after surgery. Rats had been pre-fed a high-fat (60% fat/
energy) and high-cholesterol (1.25%) diet for 7 weeks before sur-
gery, and were maintained on the same diets after surgery. On the 
day of surgery, sham-operated rats were randomized into rats fed 
ad libitum (AL; n = 12) or weight matched (BWM; n = 12) to the 
RYGB (n = 17) rats. For comparison, bile acid levels in age-matched 
chow-fed control animals are also shown (n = 6). Bile acid levels in 
RYGB rats were significantly higher compared to all other groups. 
Data are shown as mean ± SEM.  * p < 0.05,  * * p < 0.01,  * * * p < 
0.001, significant differences between the groups. 
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induced changes in energy expenditure  [53, 55–59] . Some 
but not all studies report increases in energy expenditure, 
but energy expenditure was often measured only over 
short time periods and then extrapolated to a 24-hour pe-
riod; hence, true effects induced by RYGB may have been 
overlooked. Further, necessary control groups were not 
always included in the studies.
 At present, mechanisms underlying altered energy 
expenditure after RYGB remain unclear. It seems that 
neither increased spontaneous physical activity nor 
higher body temperature can explain these findings as 
core body temperature was rather lower after RYGB 
(but also in weight-matched controls). However, heat 
dissipation was not assessed separately  [5] . In a recent 
study, brown adipose tissue activity remained unaltered 
after RYGB, which is consistent with the lack of in-
creased core body temperature  [5, 60] . Other factors like 
altered energy efficiency of skeletal muscle have so far 
not been tested.
 In our own experiments, we found that RYGB rats 
showed a slightly higher core temperature during the 
light phase when compared to weight-matched sham-op-
erated controls, which might have been due to increased 
food consumption and hence differences in diet-induced 
thermogenesis. In fact, diet-induced thermogenesis in re-
sponse to a 5-gram test meal was higher after RYGB than 
in body weight-matched control animals. Similarly, post-
prandial energy expenditure was also higher in human 
RYGB patients compared to patients receiving vertical 
banded gastroplasty (VBG)  [56] .
 Because RYGB, but not VBG, increases postprandial 
levels of GLP-1 and because GLP-1 and other products 
of the pre-proglucagon gene (e.g. oxyntomodulin) have 
been implicated in the control of energy expenditure, we 
recently tested whether acute modulation of the GLP-1 
system influences the RYGB-induced changes in energy 
expenditure. We found, however, that neither acute 
stimulation nor blockade of GLP-1 receptors with exen-
din-4 or exendin-9, respectively, influenced energy ex-
penditure in any group; in other words, energy expendi-
ture was higher after RGYB than sham operation, but 
remained unaltered by the manipulation of the GLP-1 
system  [40] .
 The increase in total energy expenditure in RYGB rats 
may also be explained by a higher energy requirement 
due to the massively hypertrophied small intestine  [5, 9, 
10] . The entire small bowel increased its total weight by 
approximately 75% after RYGB; as small intestinal oxy-
gen consumption has been estimated to make up for 
about 20% of total oxygen consumption  [61] , gut hyper-
trophy may at least partly explain the higher energy re-
quirement that, ultimately, may contribute to mainte-
nance of body weight loss. 
 Central Nervous System Contribution to the
Eating-Inhibitory Effects of RYGB 
 Studies about changes in CNS signaling after RYGB 
are rare. Even though peripheral signals potentially me-
diating RYGB-induced effects have not been completely 
identified, it is clear that any signal-inducing change on 
eating behavior and probably also on energy expenditure 
needs to be transmitted to the brain. Such signals may be 
transferred to the brain either via vagal or non-vagal af-
ferent nerve signaling or directly via blood circulation. A 
recent study has shown that the eating-inhibitory effect 
and subsequent body weight loss after RYGB seem to de-
pend at least in part on vagal transmission because both 
effects are more pronounced when part of the subdia-
phragmatic vagal innervation (specifically the paraesoph-
ageal neurovascular bundle) was preserved during RYGB 
surgery  [15] . Further, the decreased excitability of vagal 
efferent neurons in the dorsal motor nucleus of the vagus 
that results from diet-induced obesity can be reversed by 
RYGB in rats  [62] ; this is accompanied by an improved 
response of these neurons to CCK and GLP-1. Yet, an-
other study indicated that at least for the short-term re-
sult, vagal dissection may actually increase the effects of 
RYGB on body weight; yet, the long-term outcome did 
not differ between vagotomized and control RYGB rats 
 [63] . Further, RYGB effects seem to be independent of the 
specific vagal innervation of the portal vein and liver  [54] . 
Given the somewhat contradictory findings about the 
role of the vagus in RYGB, it will be important to study 
the specific role of other vagal fibers in more detail.
 Remarkably little is known about specific effects of 
RYGB (or other bariatric surgery procedures) on the CNS 
centers that are involved in eating control; most of the 
recent studies examined the role of the melanocortin sys-
tem given its overall importance in the control of eating 
and body weight  [64–71] . An unexplained species differ-
ence may be present; while homo- and heterozygous mel-
anocortin-4 receptor (MC4r) knockout rats appeared to 
be fully responsive to weight-reducing VSG surgery  [71] , 
homozygous MC4r knockout mice lost less weight after 
RYGB than heterozygous knockout or wild-type mice 
 [67] . The sufficiency of one functional MC4r gene was 
also confirmed in some studies including RYGB- or VSG-
operated humans  [66, 67, 71] . The important role of the 
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melanocortin system is further supported by findings in 
humans with a specific variant of the MC4 gene 
[MC4r(I251L)] which is associated with a better meta-
bolic status; in fact, carriers of this variant have improved 
surgery outcome  [68, 70] .
 An elegant study recently described potential sites of 
MC4 signaling for some of the observed RYGB effects; 
RYGB was performed in an animal model of DIO mice. 
In these mice, the RYGB-induced body weight loss is 
mainly due to an increase in energy expenditure; the mice 
are also characterized by improved insulin sensitivity 
mainly in the liver, but not skeletal muscle or adipose tis-
sue. Most of these effects were absent in MC4r knockout 
mice, but similar to the study described above with com-
plete MC4r knockouts  [67] , one functional allele was suf-
ficient to rescue the effect of RYGB  [70] ; this study clear-
ly shows that functional MC4 receptors are required for 
the effects of RYGB on energy expenditure, body weight 
and glucose metabolism in mice. Interestingly, the genet-
ic reintroduction of the MC4r in key autonomic neurons 
in the brainstem, including the cholinergic preganglionic 
motor neurons of the dorsal motor nucleus of the vagus, 
reinstated the effect of RYGB on insulin sensitivity, but 
not on body weight or obesity; in the latter respect, the 
mice behaved like (full) MC4r knockouts. In contrast, the 
reintroduction of the MC4r in cholinergic preganglionic 
neurons of both the parasympathetic and the sympathet-
ic system reinstated the RYGB effect on eating, body 
weight and adiposity; in this case, the improved insulin 
sensitivity was only secondary to weight loss  [70] . Hence, 
different populations of MC4rs seem to be critical for the 
mediation of specific aspects of RYGB surgery.
 Conclusions 
 Obesity and its related comorbidities are detrimental 
diseases for the affected individual, and they remain ma-
jor challenges to public health systems worldwide. The 
only currently available treatment options that lead to a 
clinically significant and long-lasting body weight loss 
and a reduction in obesity-related morbidity and mortal-
ity are based on surgical interventions  [2–4] . Apart from 
the ‘gold standard’ RYGB, the VSG and GB are two fre-
quently performed procedures. While the so-called re-
strictive GB procedure predominantly works by me-
chanical means, the RYGB- and VSG-related effects have 
been linked to similar changes in circulating levels of gas-
trointestinal hormones or bile acids  [8, 72, 73] . Most 
studies, however, also point out some differences and 
suggest that RYGB influences eating and energy expen-
diture, while VSG seems to reduce body weight mainly 
by an effect on eating. Despite enormous progress in the 
field, the number of studies linking these changes in a 
causal manner is still relatively small, and more work 
needs to be done to determine the necessity of many of 
the observed effects for the success of bariatric surgery. 
Similarly, even though many studies have reported al-
terations in food preferences after RYGB and VSG [re-
viewed in  74 ; see also  17, 73, 75–82 ], the necessity of these 
changes for the successful body weight loss after RYGB 
or VSG is far from clear. 
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